Skip to main content

Clinical features and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis



The recent COVID-19 outbreak in Wuhan, China, has quickly spread throughout the world. In this study, we systematically reviewed the clinical features and outcomes of pregnant women with COVID-19.


PubMed, Web of Science, EMBASE and MEDLINE were searched from January 1, 2020, to April 16, 2020. Case reports and case series of pregnant women infected with SARS-CoV-2 were included. Two reviewers screened 366 studies and 14 studies were included. Four reviewers independently extracted the features from the studies. We used a random-effects model to analyse the incidence (P) and 95% confidence interval (95% CI). Heterogeneity was assessed using the I2 statistic.


The meta-analysis included 236 pregnant women with COVID-19. The results were as follows: positive CT findings (71%; 95% CI, 0.49–0.93), caesarean section (65%; 95% CI, 0.42–0.87), fever (51%; 95% CI, 0.35–0.67), lymphopenia (49%; 95% CI, 0.29–0.70), coexisting disorders (33%; 95% CI, 0.21–0.44), cough (31%; 95% CI, 0.23–0.39), fetal distress (29%; 95% CI, 0.08–0.49), preterm labor (23%; 95% CI, 0.14–0.32), and severe case or death (12%; 95% CI, 0.03–0.20). The subgroup analysis showed that compared with non-pregnant patients, pregnant women with COVID-19 had significantly lower incidences of fever (pregnant women, 51%; non-pregnant patients, 91%; P < 0.00001) and cough (pregnant women, 31%; non-pregnant patients, 67%; P < 0.0001).


The incidences of fever, cough and positive CT findings in pregnant women with COVID-19 are less than those in the normal population with COVID-19, but the rate of preterm labor is higher among pregnant with COVID-19 than among normal pregnant women. There is currently no evidence that COVID-19 can spread through vertical transmission.

Peer Review reports


Unexplained clusters of pneumonia cases related to the south China seafood wholesale market were reported in Wuhan City, Hubei Province, China, in December 2019 [1]. Chinese scientists isolated the novel coronavirus from patients, sequenced the genome, and found that the genetic sequence of the virus was at least 70% similar to that of human severe acute respiratory syndrome coronavirus (SARS-CoV). The World Health Organization (WHO) named the novel coronavirus 2019-nCoV [2], also called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) [3]. As of June 6, 2020, more than 84,000 cases have been confirmed in China, and 6,728,000 cases have been confirmed worldwide [4].

Both SARS-CoV-2 and SARS-CoV are β-coronaviruses. The mortality rate of SARS-CoV infection is 10%, including a mortality rate of 25% for maternal infection [5]. The clinical outcomes of pregnant women are worse than those of non-pregnant women. To date, clinical data on pregnant women with SARS-CoV-2 are very limited. Therefore, we conducted this systematic review and meta-analysis to assess the clinical features and pregnancy outcomes of pregnant women with COVID-19 to help formulate clinical treatment strategies.


Search strategy

The protocol for the meta-analysis was based on the MOOSE (Meta-analysis Of Observational Studies in Epidemiology) checklist [6] and EQUATOR Reporting Guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [7]. We only conducted a literature review; thus, ethics approval was not required.

We systematically searched the literature in the PubMed, Web of Science, EMBASE, and MEDLINE databases. The retrieval period was from January 1, 2020, to April 16, 2020. The search keywords were as follows: ((COVID-19) OR (2019 novel coronavirus infection) OR (COVID19) OR (coronavirus disease 2019) OR (coronavirus disease-19) OR (2019-nCoV disease) OR (2019 novel coronavirus disease) OR (2019-nCoV infection) OR (SARS-CoV-2) OR (Wuhan coronavirus) OR (Wuhan seafood market pneumonia virus) OR (COVID19 virus) OR (COVID-19 virus) OR (coronavirus disease 2019 virus) OR (SARS-CoV-2) OR (SARS2) OR (2019-nCoV) OR (2019 novel coronavirus)) AND ((Pregnancy) OR (Pregnancies) OR (Gestation) OR (Pregnant Women) OR (Pregnant Woman) OR (Woman, Pregnant) OR (Women, Pregnant)). The literature search had no language restrictions. We used the Endnote X7 library (Clarivate Analytics, Philadelphia, PA, USA) to remove duplicate citations and manage the references. We hand-searched the bibliographies of the retrieved papers for additional references.

Selection criteria

Inclusion criteria

  1. 1)

    Case reports, case series and observational studies of pregnant women with COVID-19.

  2. 2)

    Description of the clinical features and/or outcomes of the patient and the foetus/new-born.

Exclusion criteria

  1. 1)

    Literature that has been republished;

  2. 2)

    Article types including authors’ replies, editorials, guidelines;

  3. 3)

    Case reports, case series and observational studies that have a number of cases less than 5;

  4. 4)

    Literature with incomplete or missing data.

Data extraction and analysis

Data extraction

The two reviewers (LY and JS.Z) independently screened the literature based on the search strategy, inclusion criteria and exclusion criteria and extracted relevant data. When the reviewers’ opinions were inconsistent, they sought the opinion of the third reviewer (YJ.G) or negotiated solutions.

Quality assessment

Four reviewers (YJ.G, YX.Y, ML, and HB. Y) independently extracted the following features of the literature, listed in the study characteristics section: first author, publication date, study date, the number and age of patients and the number of severe cases or deaths, fever, cough, lymphopenia, positive CT findings, coexisting disorders, preterm labor, caesarean section, fetal distress, neonatal asphyxia or neonatal death or stillbirth, neonatal infection, and virus in the breast milk. They also evaluated the quality of the literature using the Institute of Health Economics (IHE) case series methodological quality evaluation tool [8], which evaluated 8 areas of the literature: (1) Research purpose, (2) Research population, (3) Intervention and joint intervention, (4) Outcome measures, (5) Statistical analysis, (6) Results and conclusions, (7) Conflict of interest and funding sources, and (8) New entry. Of the aforementioned 20 items that were extracted and evaluated for each study, studies that provided information related to 14 (70%) or more of the items were considered to be of acceptable quality.

Statistical analysis

All calculations were performed with Review Manager software (version 5.3, Nordic Cochrane Centre) and were guided by the previous work, Implement Meta-Analysis with Non-Comparative Binary Data in RevMan Software [9]. The I2 statistic was used to assess heterogeneity among the studies. An I2of less than 25% indicated low heterogeneity, 25–50% indicated medium heterogeneity, and more than 50% indicated high heterogeneity. Because of the high heterogeneity of this study, we used a random effects model to pool the study-specific frequencies and 95% confidence intervals (95% CIs) of the clinical features or outcomes. A P < 0.05 using the Cochran’s Q test was considered statistically significant. Funnel plots were used to assess the publication bias. A subgroup analysis was used to assess the sensitivity.


Study selection

A total of 364 relevant documents were retrieved by the search methods above, including 103 articles from PubMed, 96 articles from Web of Science, 66 articles from EMBASE, and 99 articles from MEDLINE. We hand-searched the bibliographies of the retrieved papers, and 2 additional articles were included. After the removal of 248 duplicate documents, 82 papers were deemed ineligible after the title and abstract screening, and 22 papers were excluded after further screening through reading the full text. After the exclusion of all 352 unqualified studies, a total of 14 retrospective case analyses were included in this meta-analysis [10,11,12,13,14,15,16,17,18,19,20,21,22,23]. The process of the study selection is illustrated in Fig. 1.

Fig. 1

PRISMA flow diagram of study process

Study characteristics

We extracted the features of the literature above. The study included 236 pregnant women with laboratory-confirmed COVID-19 from December 8, 2019, to April 4, 2020, of whom 160 were in China and 76 were in America. The characteristics of the included literature are presented in Table 1.

Table 1 Characteristics of the studies included in the meta-analysis

Assessment of quality

We evaluated the quality of the fourteen included documents according to the IHE case series methodological quality evaluation tool. Thirteen articles had quality values ranging from 45 to 65%, all of which were of low quality because the values were lower than 70%. Only one article had a quality value that reached 70% and was considered to be of acceptable quality. These articles were all retrospective studies with few cases and without control groups, interventions or blind methods, so they were rated as low quality. However, these are the only published documents at present, which necessitated their inclusion. The literature quality assessment is shown in Table 2.

Table 2 Literature quality assessment with IHE case series methodological quality evaluation tool

Quantitative data synthesis

Because of the high heterogeneity of this study, we used a random effects model. The meta-analysis showed the following results: the incidence of severe case or death was 12, 95% CI: 0.03–0.20, I2 = 0%, P = 0.006; the incidence of fever was 51, 95% CI: 0.35–0.67, I2 = 89%, P < 0.00001; the incidence of cough was 31, 95% CI: 0.23–0.39, I2 = 38%, P < 0.00001; the incidence of lymphopenia was 49, 95% CI: 0.29–0.70, I2 = 83%, P < 0.00001; the incidence of positive CT findings was 71, 95% CI: 0.49–0.93, I2 = 90%, P < 0.00001; the incidence of coexisting disorders was 33, 95% CI: 0.21–0.44, I2 = 70%, P < 0.00001; the incidence of preterm labor was 23, 95% CI: 0.14–0.32, I2 = 21%, P < 0.00001; the incidence of caesarean section was 65, 95% CI: 0.42–0.87, I2 = 90%, P < 0.00001; the incidence of fetal distress was 29, 95% CI: 0.08–0.49, I2 = 68%, P = 0.007; the incidence of neonatal asphyxia or neonatal death or stillbirth was 9, 95% CI: − 0.03-0.21, I2 = 0%, P = 0.14; the incidence of neonatal infection was 12, 95% CI: − 0.01-0.26, I2 = 0%, P = 0.06; and SARS-CoV-2 testing of breast milk was only mentioned in the study by Chen H (2020.2.12), and the incidence was 0, which cannot be calculated by meta-analysis.

In summary, the P values of neonatal asphyxia or neonatal death or stillbirth and neonatal infection were both greater than 0.05, which were not statistically significant. We also could not calculate the incidence of a positive SARS-CoV-2 testing in breast milk. Otherwise, the P values in the remaining indicators were all less than 0.05 and were statistically significant. The most common clinical features were positive CT findings (71%), caesarean section (65%), and fever (51%), followed by lymphopenia (49%), cough (31%) and severe case or death (12%). Adverse pregnancy outcomes included coexisting disorders (33%), fetal distress (29%) and preterm labor (23%), in descending order. Among these indicators, the I2 value of severe cases or deaths was 0%, which indicated low heterogeneity. Although the indicators mentioned above refer to 10 studies, the incidences in eight documents were all 0, and there were only two non-zero indicator data points. The I2 value of preterm labor was 21%, which indicated low heterogeneity. The I2 value of cough was 38%, which indicated medium heterogeneity, and the remaining I2 values of indicators ranged from 68 to 90%, which indicated high heterogeneity.

Furthermore, we carried out a subgroup analysis based on the data from the fourteen retrospective analyses of COVID-19 infection in the pregnant women above and one meta-analysis of the epidemiology of all the patients COVID-19 [24]. All the patients were divided into two subgroups, namely, pregnant women and non-pregnant patients. In the fifteen articles, only two indices, i.e., fever and cough, were coincident, and were analyzed in subgroups. The results were as follows. The incidence of fever in the pregnant women was 51%, which was significantly lower than the 91% fever incidence in the non-pregnant patients (P < 0.00001). The incidence of cough in the pregnant women was also significantly lower than that in the non-pregnant patients (31% vs 67%, P < 0.0001). The forest plot of the subgroup analysis is illustrated in Figs. 2 and 3.

Fig. 2

The forest plot of subgroup analysis of fever

Fig. 3

The forest plot of subgroup analysis of cough

Risk of publication bias

The funnel plots of fever, cough, positive CT findings and coexisting disorders were symmetric, which meant that these indicators may not have publication bias. In contrast, the funnel plots of severe case or death, lymphopenia, preterm labor, caesarean section, fetal distress, neonatal asphyxia or neonatal death or stillbirth and neonatal infection were asymmetric, which meant that the indicators above may have publication bias. Since there was only 1 article about SARS-CoV-2 testing of breast milk, it was meaningless to draw a funnel plot; therefore, publication bias was not evaluated. The funnel plots of fever and cough are shown in Figs. 4 and 5.

Fig. 4

Funnel plot of fever

Fig. 5

Funnel plot of cough


Main findings

The cases discussed in this article involved 160 pregnant women with COVID-19 in China and 76 pregnant women with COVID-19 in America. The pooled results of this meta-analysis showed that among the pregnant women with COVID-19, 71% had positive CT findings, 65% had a caesarean section, 51% had fever, 49% had lymphopenia in laboratory examination, 33% had coexisting disorders, 31% had cough, 29% had fetal distress, 23% had preterm labor and 12% had severe cases or died. Pregnant women with COVID-19 had significantly lower rates of fever and cough than non-pregnant patients with COVID-19.

Strengths and limitations

Currently, there are only meta-analyses of the epidemiology of typical patients infected with COVID-19, and there are few meta-analyses to explore the clinical features and outcomes of pregnant women with COVID-19. This study is helpful to formulate clinical treatment strategies for pregnant women with COVID-19.

The disadvantage of this study was the small sample size and the general quality of the included documents, which lowered the credibility of the meta-analysis results. In addition, all the included articles were retrospective case analyses without control groups, which also biased the results. Furthermore, the funnel plots showed that most indicators may have publication bias. Most of the included patients were Chinese, and the others were American. There are few reports describing the cases outside the two regions. Further research on pregnant women with COVID-19 worldwide is needed.


We referred to the normal population the non-pregnant group to distinguish it from the pregnant group in the subgroup analysis. The subgroup analysis between pregnant women with COVID-19 and non-pregnant patients with COVID-19 showed that the incidences of fever and cough in pregnant women with COVID-19 (51, 31%) were lower than those in normal people (91, 67%), which may be due to the changes in the immune system of pregnant women, and further research is needed. The available data do show no increased or even lower maternal mortality rate after infection [25], but it does not mean that pregnancy is a protective factor for severe infection. It was reported that severe infection mostly occurred in the elderly (> 60 years old), patients with basic diseases, such as diabetes, obesity, hypertension, coronary heart disease, cerebrovascular diseases, and other chronic diseases [26,27,28,29,30], as well as those who did not receive timely treatment or delay treatment [31]. Pregnant women are usually younger without primary diseases. Besides, pregnant women are usually more likely to receive attention after the onset of the disease (pregnant women themselves, family members, and medical staff), with fewer delays in treatment. All these can explain the low fatality rate of infected pregnant women. There is no evidence that pregnancy can alleviate the disease yet, which needs further study. Aya Mohr-Sasson et al. compared clinical characteristics between pregnant women and non-pregnant women. The study showed that there were no statistical differences in clinical features such as respiratory symptoms and fever between the two groups [32]. It was reported that male patients were likely to develop more severe symptoms and have higher prevalence rates and mortality rates than female patients [33,34,35]. Zeng F et al. showed that compared with male patients, more female patients were generating a relatively high level of SARS-CoV-2 IgG antibody in severe cases, and the IgG antibody presented a stronger production in female patients in disease early phase [36]. It may be the reason why the clinical characteristics of the pregnant group in this study are better than those of the non-pregnant group. A study from the China CDC showed that 80.9% of Chinese patients were considered to be asymptomatic or to have mild pneumonia [37]. Desmond Sutton et al. showed that of the 215 pregnant women who gave birth at the New York-Presbyterian Allen Hospital and Columbia University Irving Medical Center, 29 (87.9%) of the 33 patients who were positive for SARS-CoV-2 testing had no symptoms of COVID-19 at the time of admission [19]. The fact that the asymptomatic rate in the infected general population in China is lower than the rate in infected pregnant women in the New York Medical Center seems to support this conclusion in this study. These findings suggest that the SARS-CoV-2 testing should be universally administered in high-risk areas to improve the isolation of asymptomatic infected individuals. This result is different from the finding that pregnant women infected with SARS-CoV have a worse prognosis than ordinary people infected with SARS-CoV [38]. It is possible that in pregnant women, the clinical outcome of COVID-19 infection is better than that of SARS-CoV. Yan et al. confirmed that the current mortality rate of COVID-19(2%) is significantly lower than that of SARS (9.6%), which may indicate that SARS is more pathogenic and lethal than COVID-19; thus, pregnant women with COVID-19 infection had better outcomes than those with SARS-CoV [39]. However, our finding that pregnant women with COVID-19 had better clinical features might be biased owing to the relatively small sample included in this meta-analysis.

A meta-analysis showed that the CT positive rate of COVID-19 in the normal population was 89.76% [40], which was more than the 71% positive rate in this paper. This finding also corresponded to the conclusion above that the clinical features of pregnant women with COVID-19 were superior to those of the general population. The incidence of positive CT findings was the highest among the selected indicators. Shital J. Patel et al. confirmed that chest CT was considered a low-dose examination, provided the foetus was excluded from the primary beam, and the estimated radiation doses were too low to induce foetus neurologic deficits during any trimester of pregnancy [41]. It seemed that chest CT was suitable for routine screening of patients. However, there was a large percentage of pregnant women with asymptomatic infections (87.9%) [19]. If chest CT is used for routine screening, it means that almost all pregnant women need to undergo chest CT. In addition, the WHO defines screening as the presumptive identification of unrecognized disease in an apparently healthy, asymptomatic population by means of tests, examinations or other procedures that can be applied rapidly and easily to the target population [42]. Consequently, it is not appropriate to perform chest CT as a screening tool for pregnant women with COVID-19. We recommend using chest CT as the routine examination for suspected cases.

The rate of preterm labor in normal pregnant women who are healthy and not infected with any virus worldwide is approximately 11% [43], which is lower than the result in this article (23%). The possible reason for the higher rate is that women in the third trimester of pregnancy induce delivery early after becoming ill with COVID-19 to proceed with further treatment. Most of these women choose early delivery by caesarean section to avoid a prolonged labor, which may worsen COVID-19 for pregnant women [44] and increase the risk of infection for the medical staff [45]. Chen R et al. confirmed that both epidural anesthesia and general anesthesia were safe and effective for women with COVID-19 during caesarean section [12].

Because the P value was greater than 0.05, the rate of neonatal COVID-19 infection should not be considered. Wang S et al. reported the first case in China in which a mother with COVID-19 gave birth to an infected baby on February 2, 2020 [46], and the instant SARS-CoV-2 nucleic acid tests of the umbilical cord blood and placenta were both negative. There were 3 infected neonates in the included literature. Khan S. et al. reported that the swab samples tested within 24 h after delivery were positive in two neonates, and intrauterine tissue samples such as placenta, cord blood or amniotic fluid were not tested [14]. Yu N et al. reported that the nucleic acid test for the throat swab of one neonate was positive at 36 h after birth [22]. Without testing the intrauterine tissue samples, we could not confirm whether the SARS-COV-2 infection in the neonate was the result of intrauterine transmission. Two studies also showed that the test for SARS-CoV-2-specific antibodies (IgG and IgM) in neonatal serum samples could be evidence of vertical transmission [47, 48]. Other literature revealed that almost all the other new-borns from infected women tested negative for SARS-CoV-2 [10,11,12,13, 15,16,17,18,19,20,21, 23, 49,50,51,52]. Wang C et al. summarized that there was currently no evidence for intrauterine infection caused by vertical transmission in women with COVID-19 during the third trimester of pregnancy, but it was uncertain whether there could be a risk of vertical transmission when the COVID-19 infection occurs in the first or second trimester or when there was a long clinical manifestation-to-delivery interval [53]. Therefore, we must remain alert to the possibility of vertical transmission.


The incidence of fever, cough and positive CT findings in pregnant women with COVID-19 is less than that in the normal population with COVID-19. The rate of preterm labor in normal pregnant women worldwide who are healthy and not infected with any virus is lower than that in pregnant women with COVID-19. There is currently no evidence that COVID-19 can spread through vertical transmission. The conclusions above are possibly helpful to formulate clinical treatment strategies for pregnant women with COVID-19.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.












the MOOSE checklist:


EQUATOR Reporting Guidelines:


IHE case series methodological quality evaluation tool:


95% CI:



  1. 1.

    WHO. Novel coronavirus – China. Jan 12, 2020. []. Accessed 16 Apr 2020.

  2. 2.

    Hui DS, EIA, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, TD MH, Memish ZA, Drosten C, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–6.

    CAS  Article  Google Scholar 

  3. 3.

    WHO. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020 []. Accessed 16 Apr 2020.

  4. 4.

    DXY.DX Doctor COVID-19 Global Pandemic Real-time Report []. Accessed 6 June 2020.

  5. 5.

    WHO.Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. []. Accessed 16 Apr 2020.

  6. 6.

    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. Jama. 2000;283(15):2008–12.

    CAS  Article  Google Scholar 

  7. 7.

    Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

    Article  Google Scholar 

  8. 8.

    Wang XQ, Chen YL, Qu QY, Yao L, Wei D, Wang Q, Chen G, Yang KH. Interpretation of methodological quality assessment tools for case series studies. Chin J Evid Based Pediatrics. 2015;5(10).

  9. 9.

    Chen YH, Du L, Geng XY, Liu GJ. Implement meta-analysis with non-comparative binary data in RevMan soft ware. Chin J Evid Based Med. 2014;14(7):889–96.

    Google Scholar 

  10. 10.

    Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, Ring L, Landau R, Purisch S, Friedman AM, et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of new York City hospitals. Am J Obstetrics Gynecol. 2020;100118.

  11. 11.

    Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet (London, England). 2020;395(10226):809–15.

    CAS  Article  Google Scholar 

  12. 12.

    Chen R, Zhang Y, Huang L, Cheng BH, Xia ZY, Meng QT. Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2020;67(6):655-663.

  13. 13.

    Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. J Med Virol. 2020.

  14. 14.

    Khan S, Jun L, Nawsherwan, Siddique R, Li Y, Han G, Xue M, Nabi G, Liu J Association of COVID-19 with pregnancy outcomes in health-care workers and general women. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26(6):788–790.

  15. 15.

    Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K, Yue L, Li Q, Sun G, Chen L, et al. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study. Clin Infect Dis. 2020.

  16. 16.

    Liu D, Li L, Wu X, Zheng D, Wang J, Yang L, Zheng C. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR American journal of roentgenology. 2020;215(1):127–132.

  17. 17.

    Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. The Journal of infection. 2020;80(5):e7–e13.

  18. 18.

    Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect. 2020:381–385.

  19. 19.

    Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. The New England journal of medicine. 2020;382(22):2163–2164.

  20. 20.

    Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2020;150(1):58–63.

  21. 21.

    Yang H, Sun G, Tang F, Peng M, Gao Y, Peng J, Xie H, Zhao Y, Jin Z. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019. J Infect. 2020;81(1):e40–e44.

  22. 22.

    Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, Liu Y, Xiao J, Liu H, Deng D, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis. 2020.

  23. 23.

    Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, Xia S, Zhou W. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatrics. 2020;9(1):51–60.

    Article  Google Scholar 

  24. 24.

    Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2020;94:91–95.

  25. 25.

    Segars J, Katler Q, McQueen DB, Kotlyar A, Glenn T, Knight Z, Feinberg EC, Taylor HS, Toner JP, Kawwass JF. Prior and novel coronaviruses, coronavirus disease 2019 (COVID-19), and human reproduction: what is known? Fertil Steril. 2020;113(6):1140–9.

    CAS  Article  Google Scholar 

  26. 26.

    Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.

    CAS  Article  Google Scholar 

  27. 27.

    Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–9.

    CAS  Article  Google Scholar 

  28. 28.

    Malik YS, Kumar N, Sircar S, Kaushik R, Bhat S, Dhama K, Gupta P, Goyal K, Singh MP, Ghoshal U, et al. Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective. Pathogens (Basel, Switzerland). 2020;9(7).

  29. 29.

    Vas P, Hopkins D, Feher MD, Rubino F, Martin MB. Diabetes, Obesity and COVID-19: A Complex Interplay. Diabetes Obesity Metab. 2020.

  30. 30.

    Rahimi L, Malek M, Ismail-Beigi F, Khamseh ME. Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. Adv Ther. 2020;37(8):3450–3462.

  31. 31.

    Y, Xu B, Sun B, Han G, Zhou YH. Importance of timely management of patients in reducing fatality rate of coronavirus disease 2019 J Infect Public Health. 2020;13(6):890–2.

  32. 32.

    Mohr-Sasson A, Chayo J, Bart Y, Meyer R, Sivan E, Mazaki-Tovi S, Yinon Y. Laboratory characteristics of pregnant compared to non-pregnant women infected with SARS-CoV-2. Arch Gynecol Obstet. 2020:1–6.

  33. 33.

    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 Novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497–506.

    CAS  Article  Google Scholar 

  34. 34.

    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

    CAS  Article  Google Scholar 

  35. 35.

    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054–62.

    CAS  Article  Google Scholar 

  36. 36.

    Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, Hu G, Wang Z, Zheng F, Wang L. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020.

  37. 37.

    Epidemiology working group for NCIP epidemic response, chinese center for disease control and prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–51.

  38. 38.

    Lam CM, Wong SF, Leung TN, Chow KM, Yu WC, Wong TY, Lai ST, Ho LC. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG. 2004;111(8):771–4.

    Article  Google Scholar 

  39. 39.

    Yan Y, Shin WI, Pang YX, Meng Y, Lai J, You C, Zhao H, Lester E, Wu T, Pang CH. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. Int J Environ Res Public Health. 2020;17(7).

  40. 40.

    Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis. J Am Coll Radiol. 2020;17(6):701–709.

  41. 41.

    Patel SJ, Reede DL, Katz DS, Subramaniam R, Amorosa JK. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. Radiographics. 2007;27(6):1705–22.

    Article  Google Scholar 

  42. 42.

    WHO. Cancer: Screening []. Accessed 16 Apr 2020.

  43. 43.

    Vogel JP, Chawanpaiboon S, Moller AB, Watananirun K, Bonet M, Lumbiganon P. The global epidemiology of preterm birth. Best Pract Res Clin Obstetrics Gynaecol. 2018;52:3–12.

    Article  Google Scholar 

  44. 44.

    Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, Fan S, Feng L, Gao Y, He F, et, al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2020;149(2):130–136.

  45. 45.

    Bauer ME, Bernstein K, Dinges E, Delgado C, El-Sharawi N, Sultan P, Mhyre JM, Landau R. Obstetric Anesthesia During the COVID-19 Pandemic. Anesth Analg. 2020;131(1):7–15.

  46. 46.

    Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, Feng L. A case report of neonatal COVID-19 infection in China. Clin Infect Dis. 2020.

  47. 47.

    Dong L, Tian J, He S, Zhu C, Wang J, Liu C, Yang J. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. Jama. 2020;323(18):1846–1848.

  48. 48.

    Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, Long X. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. Jama. 2020;323(18):1848–1849.

  49. 49.

    Chen S, Huang B, Luo DJ, Li X, Yang F, Zhao Y, Nie X, Huang BX. Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases. Zhonghua Bing Li Xue Za Zhi. 2020;49(0):E005.

    Google Scholar 

  50. 50.

    Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, Bao Y, Sun Y, Huang J, Guo Y, et al. Perinatal transmission of COVID-19 associated SARS-CoV-2: should we worry? Clin Infect Dis. 2020.

  51. 51.

    Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery. Clin Infect Dis. 2020.

  52. 52.

    Wen R, Sun Y, Xing QS. A patient with SARS-CoV-2 infection during pregnancy in Qingdao, China. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020;53(3):499–500.

  53. 53.

    Wang C, Zhou YH, Yang HX, Poon LC. Intrauterine vertical transmission of SARS-CoV-2: what we know so far. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2020;55(6):724–725.

Download references


Not applicable.


This work was supported by the National Natural Science Foundation of China (No. 81571465, No. 81871175). The mentioned foundation had no rule in the study design, data analysis, drafting the manuscript, or decision to submit this article for publication.

Author information




LY and JS.Z conducted the literature search and selected studies. YX.Y assessed the methodologic quality of the studies. ML and HB.Y extracted data. YJ.G conceived and planned the review, assessed the methodologic quality of the studies, verified the data, and drafted and revised the manuscript. RZ provided methodologic advice, content expertise, and revised the manuscript. All authors contributed to writing the protocol. All authors read and approved the final manuscript.

Authors’ information

Not applicable.

Corresponding author

Correspondence to Rong Zhou.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gao, Y., Ye, L., Zhang, J. et al. Clinical features and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 20, 564 (2020).

Download citation


  • SARS-CoV-2
  • COVID-19
  • Clinical features
  • Pregnancy outcomes
  • Pregnant women
  • Meta-analysis